Companies /Healthcare

Phibro Animal Health Corp - Class A

NASDAQ: PAHC Drug Manufacturers - Specialty & Generic
$38.80
▼ $1.01 (−2.54%) today
Markets closed · 7:24pm ET

PAHC at a Glance

Valuation
Market cap
$1.6B
P/E ratio
16.2
Dividend yield
1.22%
Profitability
Revenue (TTM)
$1.5B
Profit margin
6.6%
EPS (TTM)
$2.46
Price
52-week range
$28 – $60
Street target
$47.00
Earnings
Next report
Nov 4, 2026

Headquartered in Teaneck, NJ Fiscal year ends June NASDAQ: PAHC pahc.com

About Phibro Animal Health

Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company that serves livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals. The company operates through three segments: Animal Health (including medicated feed additives/MFAs, nutritional specialties, and vaccines), Mineral Nutrition (zinc, copper, and trace minerals for animal feed), and Performance Products (specialty chemicals including copper-based products and ingredients for personal care). Phibro's Animal Health segment, which generates the majority of revenue, offers antimicrobials, nutritional specialty products for dairy and other livestock, and poultry vaccines with particular strength in Latin America and Israel. The company completed a significant MFA portfolio acquisition in October 2024 that expanded its manufacturing footprint and product range. Phibro also operates an ethanol performance business providing antimicrobials and processing aids to the fermentation industry. The company sells its products globally with meaningful operations in North America, Latin America, Israel, and Southeast Asia. Updated

PAHC Coverage

Frequently Asked Questions

What does Phibro Animal Health do?

Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company that serves livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals.

What is the PAHC stock price target?

The Wall Street consensus 12-month price target for PAHC is $47.00.